Abstract
This research investigated the role of Membrane Palmitoylated Protein 2 (MPP2) in colon adenocarcinoma (COAD), the third most prevalent form of colorectal cancer. Utilizing TCGA, GEPIA, and HPA datasets alongside Western blotting, we examined MPP2 expression in normal versus cancerous tissue. Kaplan-Meier plots from GEPIA indicated lower MPP2 levels in COAD patients correlating with worse overall survival (P < 0.05). Moreover, MPP2 was identified as a distinct prognostic indicator for COAD and significantly associated with clinicopathological features (P < 0.05), assessed via chi-square tests and Cox regression models. We further explored MPP2’s link to COAD immune cells using Cibersort, revealing its correlation with the infiltration of 8 immune cells (P < 0.05). In vivo and in vitro experiments demonstrated that elevated MPP2 levels might enhance cell proliferation and migration while suppressing apoptosis. Applying Gene Set Enrichment Analysis (GSEA), we predicted MPP2’s involvement in tumor progression via the DNA sensing pathway, a finding supported by cellular studies. In summary, COAD patients exhibit decreased MPP2 expression, which inversely correlates with prognosis. MPP2 appears to influence immunosuppression and tumor progression through various mechanisms, suggesting its potential as an independent prognostic marker in COAD. Further investigation into MPP2’s implications is warranted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
